Form4insider filings, from the source

SEC Form 4 · accession 0001225208-17-009193

Edwards Lifesciences Corp · EW

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael A Mussallem
Officer — Chairman & CEO · Director
Period of report
May 3, 2017
Accepted (ET)
May 4, 2017 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2May 3, 2017M48,900$25.48A78,884D
Common StockF2May 3, 2017M200$44.615A79,084D
Common StockF2May 3, 2017S300$110.20D78,784D
Common StockF3,F2May 3, 2017S48,800$109.7078D29,984D
Common StockF4holding———123,931I401(k)
Common Stockholding———676,295IBy Living Trust

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Acquire)F2$44.615May 3, 2017M200DJun 12, 2011May 11, 2018Common Stock200381,200D
Employee Stock Option (Right to Acquire)F2$25.48May 3, 2017M48,900DJun 13, 2010May 12, 2017Common Stock48,9000D

Explanation of responses